{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:38:33Z","timestamp":1786700313714,"version":"build-2736575974"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dutch Medical Science Foundation ZonMW","award":["636340001"],"award-info":[{"award-number":["636340001"]}]},{"name":"Dutch Medical Science Foundation ZonMW","award":["348041003"],"award-info":[{"award-number":["348041003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Hypothesis<\/jats:title>\n                    <jats:p>The extent to which tapering antipsychotic (AP) attenuates AP-related movement disorders and cardiometabolic dysfunction remains unclear. We aim to investigate the long-term effects of AP-dose reduction on these adverse effects in patients remitted from a first episode of psychosis (FEP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Methods<\/jats:title>\n                    <jats:p>We included 293 FEP participants from the HAMLETT trial. Movement disorders were assessed using the St. Hans Rating Scale (SHRS) and Barnes Akathisia Rating Scale. Cardiometabolic indices included body mass index (BMI), waist circumference, blood pressure (BP), glucose, triglycerides, and cholesterol. Linear mixed-effects models assessed longitudinal relationships between AP-dose reduction, movement disorders and cardiometabolic indices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>Over an average 29-month follow-up (SD\u2009=\u200919), a 1\u00a0mg olanzapine equivalent dose reduction from baseline was associated with a 0.013-point decrease in Parkinsonism (95% CI, \u22120.019, \u22120.006), a potential 0.003-point decrease in tardive dyskinesia (95% CI, \u22120.006, \u22120.000) on SHRS (range 0-6), and decreases of 0.037 (0.15%) kg\/m2 in BMI (95% CI, \u22120.059, \u22120.015), 0.153 (0.17%) cm in waist circumference (95% CI, \u22120.265, \u22120.037), 0.023 (0.47%) mmol\/L in total cholesterol (95% CI, \u22120.039, \u22120.007), 0.018 (0.60%) mmol\/L in low-density lipoprotein cholesterol (95% CI, \u22120.032, \u22120.003), and 0.021 (0.58%) mmol\/L in nonhigh-density lipoprotein cholesterol (95% CI, \u22120.037, \u22120.005). We found no evidence for an association with tardive dystonia, akathisia, BP, glucose, or triglycerides.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AP-dose reduction modestly benefits AP-related Parkinsonism, weight gain, cholesterol levels and potentially tardive dyskinesia in patients after FEP over time. These benefits should be carefully weighed against the risks of relapse and suicide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbaf116","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T07:50:49Z","timestamp":1751097049000},"source":"Crossref","is-referenced-by-count":1,"title":["The Effects of Antipsychotic Dose Reduction on Movement Disorders and Cardiometabolic Indices in Patients Remitted from a First Episode of Psychosis"],"prefix":"10.1093","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4156-4852","authenticated-orcid":false,"given":"Yinzhao","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Cognitive Neuroscience Center, University Medical Center Groningen (UMCG), University of Groningen , Groningen 9713 GZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E","family":"Sommer","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cognitive Neuroscience Center, University Medical Center Groningen (UMCG), University of Groningen , Groningen 9713 GZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-2799","authenticated-orcid":false,"given":"Marieke J H","family":"Begemann","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cognitive Neuroscience Center, University Medical Center Groningen (UMCG), University of Groningen , Groningen 9713 GZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0084-8226","authenticated-orcid":false,"given":"Shiral S","family":"Gangadin","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cognitive Neuroscience Center, University Medical Center Groningen (UMCG), University of Groningen , Groningen 9713 GZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin I","family":"Perry","sequence":"additional","affiliation":[{"name":"Institute for Mental Health, University of Birmingham , Birmingham B15 2TT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toon A W","family":"Scheurink","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cognitive Neuroscience Center, University Medical Center Groningen (UMCG), University of Groningen , Groningen 9713 GZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico J M","family":"van Beveren","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cognitive Neuroscience Center, University Medical Center Groningen (UMCG), University of Groningen , Groningen 9713 GZ ,","place":["The Netherlands"]},{"name":"Parnassia Group for Mental Health Care , The Hague 2552 KS ,","place":["The Netherlands"]},{"name":"Department of Neuroscience, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]},{"name":"Department of Psychiatry, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"HAMLETT and OPHELIA Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieuwe","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Veling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"van Os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Begemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machteld","family":"Marcelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Kikkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"van Beveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke","family":"Boonstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram-Sieben","family":"Rosema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"G\u00fcl\u00f6ks\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joran","family":"Lokkerbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Wijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodyl","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiral","family":"Gangadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erna","family":"van\u2019t Hag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Oomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Voppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franciska","family":"de Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sterre","family":"Kamphuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Hamers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toon","family":"Scheurink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jort","family":"Noorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"van Amelsvoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Bak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Berendsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truus","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Grootens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henderikus","family":"Knegtering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kurkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerdina Hendrika Maria","family":"Pijnenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Staring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybren","family":"Wiersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Batalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Curfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Jaap","family":"Hage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Graveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Hoornaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Hobus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Huizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Roberto","family":"Bakker","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cognitive Neuroscience Center, University Medical Center Groningen (UMCG), University of Groningen , Groningen 9713 GZ ,","place":["The Netherlands"]},{"name":"Arkin, Institute for Mental Health , Amsterdam 1033 NN ,","place":["The Netherlands"]},{"name":"Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MheNS), Maastricht University Medical Centre , Maastricht 6229 ER ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Koops","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Cognitive Neuroscience Center, University Medical Center Groningen (UMCG), University of Groningen , Groningen 9713 GZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"2026081405130285100_ref1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"2026081405130285100_ref2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"2026081405130285100_ref3","doi-asserted-by":"crossref","first-page":"e0257129","DOI":"10.1371\/journal.pone.0257129","article-title":"Antipsychotic-induced extrapyramidal side effects: a systematic review and meta-analysis of observational studies","volume":"16","author":"Ali","year":"2021","journal-title":"PLoS One"},{"key":"2026081405130285100_ref4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1089\/met.2023.0003","article-title":"Antipsychotic-induced metabolic syndrome: a review","volume":"21","author":"Akinola","year":"2023","journal-title":"Metab Syndr Relat Disord"},{"key":"2026081405130285100_ref5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.psychres.2016.01.069","article-title":"The longitudinal trends in the relationship between drug-induced extrapyramidal symptoms and personal and social performance in a population of the patients with schizophrenia: a latent growth model","volume":"238","author":"Park","year":"2016","journal-title":"Psychiatry Res"},{"key":"2026081405130285100_ref6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"key":"2026081405130285100_ref7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/acps.13758","article-title":"The impact of weight gain on antipsychotic nonadherence or discontinuation: a systematic review and meta-analysis","volume":"151","author":"De","year":"2025","journal-title":"Acta Psychiatr Scand"},{"key":"2026081405130285100_ref8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12991-021-00348-0","article-title":"Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study","volume":"20","author":"Bahta","year":"2021","journal-title":"Ann General Psychiatry"},{"key":"2026081405130285100_ref9","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22r14490","article-title":"Comparative effects of 11 antipsychotics on weight gain and metabolic function in patients with acute schizophrenia: a dose-response meta-analysis","volume":"84","author":"Sabe","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"2026081405130285100_ref10","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis","year":"2023","journal-title":"Mol Psychiatry"},{"key":"2026081405130285100_ref11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/schbul\/sbac001","article-title":"Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials","volume":"48","author":"Wu","year":"2022","journal-title":"Schizophr Bull"},{"key":"2026081405130285100_ref12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.euroneuro.2023.03.015","article-title":"Antipsychotic-induced akathisia in adults with acute schizophrenia: a systematic review and dose-response meta-analysis","volume":"72","author":"Wu","year":"2023","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026081405130285100_ref13","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbac001","article-title":"Antipsychotic dose reduction compared to dose continuation for people with schizophrenia","volume":"11","author":"Rodolico","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026081405130285100_ref14","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S2215-0366(23)00258-4","article-title":"Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial","volume":"10","author":"Moncrieff","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"2026081405130285100_ref15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13063-019-3822-5","article-title":"To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction\/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial","volume":"21","author":"Begemann","year":"2020","journal-title":"Trials"},{"key":"2026081405130285100_ref16","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr Bull"},{"key":"2026081405130285100_ref17","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42 Suppl 1","author":"Leucht","year":"2016","journal-title":"Schizophr Bull"},{"key":"2026081405130285100_ref18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am J Psychiatry"},{"key":"2026081405130285100_ref19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/107385840000600408","article-title":"The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?","volume":"6","author":"Roth","year":"2000","journal-title":"Neuroscientist"},{"key":"2026081405130285100_ref20","doi-asserted-by":"publisher","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"2026081405130285100_ref21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2215-0366(21)00114-0","article-title":"Development and external validation of the psychosis metabolic risk calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis","volume":"8","author":"Perry","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"2026081405130285100_ref22","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"2026081405130285100_ref23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","article-title":"The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity","volume":"87","author":"Gerlach","year":"1993","journal-title":"Acta Psychiatr Scand"},{"key":"2026081405130285100_ref24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/schbul\/sbab028","article-title":"Exploring the relationship between movement disorders and physical activity in patients with schizophrenia: an actigraphy study","volume":"47","author":"Pieters","year":"2021","journal-title":"Schizophr Bull"},{"key":"2026081405130285100_ref25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12888-016-1121-1","article-title":"Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study","volume":"16","author":"Bressington","year":"2016","journal-title":"BMC Psychiatry"},{"key":"2026081405130285100_ref26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s43441-019-00026-0","article-title":"Risk of extrapyramidal syndromes associated with psychotropic polypharmacy: a study based on large-scale Japanese claims data","volume":"54","author":"Hirano","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"2026081405130285100_ref27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/wps.21089","article-title":"Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis","volume":"22","author":"Leucht","year":"2023","journal-title":"World Psychiatry"},{"key":"2026081405130285100_ref28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/acps.13776","article-title":"Initiation of antipsychotics during the first year after first-episode psychosis: a population-based study","volume":"151","author":"Odsbu","year":"2025","journal-title":"Acta Psychiatr Scand"},{"key":"2026081405130285100_ref29","doi-asserted-by":"publisher","first-page":"e2804","DOI":"10.1002\/hup.2804","article-title":"Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms","volume":"36","author":"Takeuchi","year":"2021","journal-title":"Hum Psychopharmacol"},{"key":"2026081405130285100_ref30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders","volume":"50","author":"Galletly","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"key":"2026081405130285100_ref31","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.4088\/JCP.11m07246","article-title":"Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database","volume":"73","author":"Bushe","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2026081405130285100_ref32","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.euroneuro.2014.07.001","article-title":"Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST","volume":"24","author":"Rybakowski","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026081405130285100_ref33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1176\/ajp.156.1.79","article-title":"Olanzapine versus haloperidol treatment in first-episode psychosis","volume":"156","author":"Sanger","year":"1999","journal-title":"Am J Psychiatry"},{"key":"2026081405130285100_ref34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/02698811211055812","article-title":"Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia","volume":"36","author":"Rekhi","year":"2022","journal-title":"J Psychopharmacol"},{"key":"2026081405130285100_ref35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0706743719828968","article-title":"Treatment recommendations for tardive dyskinesia","volume":"64","author":"Ricciardi","year":"2019","journal-title":"Can J Psychiatr"},{"key":"2026081405130285100_ref36","article-title":"Antipsychotic reduction and\/or cessation and antipsychotics as specific treatments for tardive dyskinesia","volume":"2","author":"Bergman","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026081405130285100_ref37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the guideline development Subcommittee of the American Academy of neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"2026081405130285100_ref38","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.4088\/JCP.16m11049","article-title":"Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: the curacao extrapyramidal syndromes study XII","volume":"78","author":"Mentzel","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"2026081405130285100_ref39","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/schbul\/sbab017","article-title":"A method for tapering antipsychotic treatment that may minimize the risk of relapse","volume":"47","author":"Horowitz","year":"2021","journal-title":"Schizophr Bull"},{"key":"2026081405130285100_ref40","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10082010","article-title":"Pathophysiological mechanisms of antipsychotic-induced parkinsonism","volume":"10","author":"Vaiman","year":"2022","journal-title":"Biomedicines"},{"key":"2026081405130285100_ref41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40263-018-0494-8","article-title":"Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies","volume":"32","author":"Stegmayer","year":"2018","journal-title":"CNS Drugs"},{"key":"2026081405130285100_ref42","first-page":"161","article-title":"Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action","volume":"25","author":"Kapur","year":"2000","journal-title":"J Psychiatry Neurosci"},{"key":"2026081405130285100_ref43","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/YCO.0000000000000598","article-title":"Dopamine D2 up-regulation in psychosis patients after antipsychotic drug treatment","volume":"33","author":"Thompson","year":"2020","journal-title":"Curr Opin Psychiatry"},{"key":"2026081405130285100_ref44","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s40265-020-01312-0","article-title":"Treatment of antipsychotic-induced akathisia: role of serotonin 5-HT(2a) receptor antagonists","volume":"80","author":"Poyurovsky","year":"2020","journal-title":"Drugs"},{"key":"2026081405130285100_ref45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881120944156","article-title":"Neurobiological mechanisms associated with antipsychotic drug-induced dystonia","volume":"35","author":"Loonen","year":"2021","journal-title":"J Psychopharmacol"},{"key":"2026081405130285100_ref46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR working group on visceral obesity","volume":"16","author":"Ross","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2026081405130285100_ref47","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026081405130285100_ref48","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.2174\/1570159X22666240212141602","article-title":"Glucose metabolism and sex hormones in male patients with medication-naive first-episode schizophrenia: a large-scale cross-sectional study","volume":"22","author":"Xiu","year":"2024","journal-title":"Curr Neuropharmacol"},{"key":"2026081405130285100_ref49","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S2215-0366(16)30262-0","article-title":"The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis","volume":"3","author":"Perry","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2026081405130285100_ref50","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030238","article-title":"Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences","volume":"14","author":"Carli","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026081405130285100_ref51","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1192\/bjp.184.4.346","article-title":"Relapse in schizophrenia: costs, clinical outcomes and quality of life","volume":"184","author":"Almond","year":"2004","journal-title":"Br J Psychiatry"},{"key":"2026081405130285100_ref52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.184.4.346","article-title":"Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study","volume":"9","author":"Stromme","year":"2024","journal-title":"Psychol Med"},{"key":"2026081405130285100_ref53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2024-301184","article-title":"Prevalence of spontaneous movement disorders (dyskinesia, parkinsonism, akathisia and dystonia) in never-treated patients with chronic and first-episode psychosis: a systematic review and meta-analysis","volume":"27","author":"Kalniunas","year":"2024","journal-title":"BMJ Ment Health"},{"key":"2026081405130285100_ref54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jpsychires.2015.04.028","article-title":"Schizoaffective disorder and metabolic syndrome: a meta-analytic comparison with schizophrenia and other non-affective psychoses","volume":"66-67","author":"Bartoli","year":"2015","journal-title":"J Psychiatr Res"},{"key":"2026081405130285100_ref55","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40265-016-0551-x","article-title":"Antipsychotic Management of Schizoaffective Disorder: a review","volume":"76","author":"Lindenmayer","year":"2016","journal-title":"Drugs"},{"key":"2026081405130285100_ref56","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.parkreldis.2020.08.031","article-title":"Movement disorders induced by psychiatric drugs that do not block dopamine receptors","volume":"79","author":"Friedman","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"2026081405130285100_ref57","doi-asserted-by":"crossref","first-page":"573479","DOI":"10.3389\/fendo.2020.573479","article-title":"Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness","volume":"11","author":"Mazereel","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026081405130285100_ref58","volume-title":"Missing Data at Different Levels. Applied Missing Data Analysis with SPSS and (R) Studio: R studio","author":"Heymans","year":"2019"},{"key":"2026081405130285100_ref59","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jclinepi.2013.03.017","article-title":"Multiple imputation of missing values was not necessary before performing a longitudinal mixed-model analysis","volume":"66","author":"Twisk","year":"2013","journal-title":"J Clin Epidemiol"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/4\/sbaf116\/64104802\/sbaf116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/4\/sbaf116\/64104802\/sbaf116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:14:28Z","timestamp":1786698868000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/doi\/10.1093\/schbul\/sbaf116\/8239455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbaf116","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2025,8,21]]},"article-number":"sbaf116"}}